5 Best Peptides for NAD+ Optimization

What to Know Before Choosing a Peptide for NAD+ Optimization

The phrase "peptides for NAD+ optimization" is used loosely in longevity communities, and that looseness is worth naming upfront. NAD+ itself is not a peptide. It is a coenzyme found in every cell in your body, and it declines significantly with age, with tissue levels falling roughly 40 to 60 percent between early adulthood and old age. The compounds people group under this umbrella share a common goal, supporting mitochondrial energy production and cellular repair, but they reach that goal through very different routes. Some supply the raw NAD+ molecule or its precursors directly. Some block the enzymes that break NAD+ down. Some help the mitochondria use what is already there more efficiently. Not all of them are peptides in the strict chemical sense, but this article covers all of them because that is what people actually use and discuss for this goal, and drawing an artificial line at "technically a peptide" would leave out the compounds the community considers essential.

A compound earned a slot on this list because people use it or are actively discussing using it for NAD+ optimization. FDA approval, the depth of clinical trial data, and whether the compound is a peptide or a small molecule all informed how each entry is described, but none of those factors determined whether something made the list. NAD+ precursors have multiple controlled human trials behind them. MOTS-c has almost no published human data. Both belong here, with their evidence described honestly.

The entries are numbered by how prominently each compound appears in research and documented real-world use for this goal, not as a recommendation of one over another. The right choice depends on your health history, your goals, and how each compound fits your broader protocol. That personalized layer belongs in the app. What this article gives you is an honest map of the field.

1. NAD+ Precursors: The Foundation of the Field

Before any peptide enters the conversation, most people working on NAD+ optimization start with precursors: the molecules the body converts directly into NAD+. The three most studied are nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and nicotinic acid (niacin). These are not peptides, but they sit at the center of every NAD+ optimization discussion because they carry the deepest human evidence base of anything in this space.

The body makes NAD+ through three distinct metabolic pathways, and each precursor enters at a different step. NR bypasses a key bottleneck enzyme called NAMPT, which becomes less active with age, making it a particularly efficient route when endogenous production has already slowed. NMN converts to NAD+ via a different enzyme called NMNAT, entering the pathway one step closer to the finished molecule. Niacin travels a longer three-step route and is currently being tested in trials for its ability to raise NAD+ in cerebrospinal fluid.

The human evidence is the strongest of anything in the NAD+ optimization category. Multiple controlled trials have shown that oral NR raises NAD+ in peripheral blood cells by roughly 40 to 90 percent depending on dose. One double-blind trial found a 26.5 percent increase in whole blood NAD+ after four weeks of supplementation with an NR-containing formula. A 2018 Nature Metabolism trial found that NMN increased circulating NAD+ in healthy adults and improved both insulin sensitivity and muscle energy metabolism. Several trials are currently registered to test NMN's effects on glucose, insulin, and lipid parameters. NR also carries GRAS (Generally Recognized as Safe) status from the FDA and has been approved as a food ingredient by regulatory bodies in Canada, Europe, and Australia.

Direct NAD+ administration via intravenous infusion or subcutaneous injection is also used, particularly in clinical settings. One important nuance: when NAD+ is delivered intravenously, it does not enter cells intact. It first breaks down extracellularly into precursor forms, which then reconstitute intracellularly. This means IV NAD+ may function more like delivering a precursor than delivering the finished molecule, which is worth understanding when evaluating the clinical rationale. Studies show NAD+ levels rise measurably after six weeks of weekly injections in clinical protocols.

Side effects are generally mild and transient: nausea, headache, flushing, and occasional fatigue are the most commonly reported. Community accounts are highly variable, with some users describing dramatic energy and sleep improvements and others reporting no effect or, less commonly, significant exhaustion or heart rate elevation. Rare but serious risks including allergic reactions and liver enzyme elevation have been reported, particularly at high doses of nicotinamide. People with active cancer, severe liver or kidney disease, or a history of severe allergic reactions are among those for whom physician oversight is especially important.

2. MOTS-c: The Mitochondrial Signaling Peptide

MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C) is a short peptide derived from mitochondrial DNA, specifically from the 12S rRNA gene. It belongs to a class called mitokines, signaling molecules that originate inside mitochondria and communicate outward to regulate metabolism across tissues. It has a genuine biological rationale for why it complements NAD+ optimization, even though it does not directly raise NAD+ levels.

The mechanism is one of efficiency rather than supply. MOTS-c depends on NAD+ to function, and when NAD+ is adequate, its metabolic effects are amplified. Think of it as a downstream beneficiary of good NAD+ status: it enhances oxidative capacity in the mitochondria and supports insulin sensitivity and glucose metabolism, but those effects are blunted if NAD+ availability is poor. In biohacking and longevity communities, MOTS-c is used alongside NAD+ precursors specifically for this synergistic quality.

The evidence base is almost entirely preclinical. No published human clinical trials exist for MOTS-c as of 2026. The available data comes from animal and in vitro studies pointing to real mitochondrial biology, but the translation to human outcomes has not been established in controlled research. Community use for longevity, endurance, and age-related energy decline is active and consistent, though those reports are experiential rather than clinical. One notable signal of recognized bioactive potential: MOTS-c is banned by the World Anti-Doping Agency (WADA), which typically reflects a judgment that a compound has meaningful performance-modifying effects even when human trial data is sparse.

MOTS-c is not FDA-approved for any indication. It is available through research chemical channels and, in some cases, via compounding pharmacy prescriptions through telehealth providers. The absence of established human safety data means anyone using it is operating with a genuinely limited picture of risk, which is worth stating plainly alongside the genuine biological interest.

3. 5-Amino-1MQ: Blocking the Breakdown Pathway

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a synthetic small molecule, not a peptide. It earns its place in NAD+ optimization discussions because it targets one of the primary drivers of NAD+ decline: an enzyme called CD38.

CD38 is an NAD+ hydrolase, meaning its job is to break NAD+ down. Its activity increases significantly with age, and this accelerated breakdown is considered one of the three main mechanisms behind age-related NAD+ depletion, alongside declining NAMPT activity and excessive PARP activation from accumulated DNA damage. 5-Amino-1MQ inhibits CD38 directly, preventing it from consuming NAD+ and effectively raising intracellular NAD+ levels without synthesizing new molecules. The strategy is to address the breakdown side of the NAD+ equation while precursors address the supply side. This pairing logic is why 5-Amino-1MQ appears consistently in advanced longevity protocols alongside NMN or NR.

The human evidence for 5-Amino-1MQ specifically is very limited. CD38 inhibition as a biological strategy is scientifically validated and appears in peer-reviewed literature, so the mechanism is real. But controlled human trials for this particular molecule are sparse as of 2026. What exists is largely community-reported use in longevity and biohacking circles, where it is combined with precursors in what practitioners describe as a more complete NAD+ stack. The compound is not FDA-approved, carries no established dosing from human trials, and is classified as an unregulated research compound available through research chemical suppliers and some telehealth compounding channels.

The gap between the soundness of the underlying mechanism and the thinness of the human clinical record is notable here. The biology of CD38 inhibition is peer-reviewed and credible. The clinical application of this specific molecule in humans is not yet backed by controlled trials, so the confidence comes from mechanism and preclinical data, not from measured human outcomes.

4. SS-31 (Elamipretide): Stabilizing the Mitochondrial Membrane

SS-31, also known as Elamipretide or MTP-131, is a synthetic tetrapeptide: four amino acids, making it the most conventionally peptide-like compound on this list. It was developed as a mitochondria-targeted therapy and has undergone more human clinical research than any other compound covered here, which makes it unusual in the longevity peptide space.

The mechanism centers on cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin plays a structural role in maintaining the architecture of the electron transport chain, which is the cellular machinery that generates ATP and cycles NAD+ from its reduced form (NADH) back to its active, oxidized form (NAD+). When cardiolipin is destabilized, the electron transport chain becomes less efficient, and NAD+ recycling slows down even when NAD+ supply is adequate. SS-31 stabilizes cardiolipin, preserving the structural integrity of the electron transport chain and improving both ATP production and the efficiency of NAD+/NADH cycling. It is not raising NAD+ levels; it is ensuring the mitochondria are equipped to use what is there.

SS-31 has been studied in human clinical trials for heart failure, Barth syndrome (a rare mitochondrial disease), age-associated muscle weakness, and mitochondrial myopathy. This is a substantially more established research pedigree than most longevity peptides carry. The results have been mixed. The PROGRESS-HF trial, a significant heart failure study, did not meet its primary endpoints. Preclinical data across multiple disease models remains compelling, and the mechanistic rationale for NAD+ optimization holds up to scrutiny, but the mixed clinical record belongs alongside the preclinical enthusiasm.

In NAD+ optimization protocols, SS-31 is included for its mitochondrial synergy: the reasoning is that raising NAD+ supply and blocking its degradation only pays off if the mitochondria are functioning well enough to use it. SS-31 is not FDA-approved as of 2026, and it is available through compounding pharmacies and research channels. Injection site reactions are the most commonly reported adverse effect in clinical settings.

5. Humanin: The Neuroprotective Mitokine

Humanin is another mitochondria-derived peptide, encoded in mitochondrial DNA and belonging to the same mitokine family as MOTS-c. It was first identified in research on Alzheimer's disease and has since been studied for a broader set of neuroprotective and metabolic effects. In the NAD+ optimization context, it appears in longevity protocols as a complementary compound, supporting cellular energy pathways and reducing mitochondrial stress rather than directly raising NAD+ levels.

The biological rationale is grounded in real pathways. Humanin interacts with insulin signaling and mitochondrial stress responses and has been associated with reduced cellular death under metabolic stress in preclinical models. Some practitioners working in anti-aging and longevity medicine include it in broader mitochondrial support protocols alongside NAD+ precursors, reasoning that the mitokine family as a whole supports the cellular environment in which NAD+ does its work.

The evidence is primarily preclinical. No large controlled human trials have established Humanin's effects on energy metabolism or NAD+ optimization in healthy adults as of 2026. The available human data comes largely from observational research and small studies in specific disease populations. Community use is active but less widespread than MOTS-c or SS-31, concentrated among researchers and advanced biohackers interested in the mitokine family. Its inclusion here reflects real and recurring discussion in longevity communities rather than a validated clinical profile, and that distinction is worth keeping in mind.

Humanin is a research compound, available through research chemical suppliers and some telehealth compounding pathways. No established safety profile from controlled human studies exists, which means its use occurs in the same limited-data context as the other peptides in this category.

How These Peptides Compare

Frequently Asked Questions

Are the compounds in this guide legal to use?

The answer depends on which compound and where you are. NAD+ precursors like NR have FDA GRAS status and are approved as food ingredients in multiple countries, making them broadly accessible. NMN occupies a regulatory gray area in some jurisdictions but is widely available. MOTS-c and Humanin are research chemicals with no FDA approval, and accessing them for human use typically means going through a compounding pharmacy via a telehealth prescription or a research chemical supplier. SS-31 is available through compounding channels despite not carrying FDA approval. Legal status changes, and verifying current status with a healthcare provider is a practical step, not just a formality.

Do these compounds work better together or separately?

Community protocols and practitioner approaches commonly combine them because they address different parts of the same problem. Precursors raise NAD+ supply. 5-Amino-1MQ prevents its degradation. SS-31 and MOTS-c improve how efficiently the mitochondria use available NAD+. The mechanistic logic of combining them is coherent, but no controlled human trial has tested a combined NAD+ optimization stack as of 2026. Whether stacking produces meaningfully better outcomes than any single compound used alone has not been established in controlled research, and the interactions between them are not well characterized in humans.

How long before someone notices a change?

Timelines vary widely and do not follow a predictable pattern. Some people in community forums describe noticing changes in energy or sleep within a few days to a week of starting NAD+ precursors. Others report nothing after three to four months. The peptides in this category have even less timeline data to draw from, given the limited human evidence base. There is no clinically validated timeline for most of these compounds in healthy adults, and anyone expecting a specific outcome within a set window is working from anecdote rather than controlled trial data.

Is SS-31 the same as Elamipretide?

Yes. SS-31, Elamipretide, and MTP-131 are all names for the same synthetic tetrapeptide. SS-31 is the research shorthand derived from the Szeto-Schiller peptide naming system. Elamipretide is the pharmaceutical name used in clinical trials. MTP-131 was an earlier development code. When you see any of these names in research or community discussions, they refer to the same compound.

What is the difference between taking NAD+ directly and taking a precursor?

The distinction matters more than it might initially appear. When NAD+ is delivered intravenously, it does not enter cells in its intact form. It first breaks down extracellularly into precursor molecules, which then reconstitute into NAD+ inside the cell. This means IV NAD+ may functionally resemble precursor delivery rather than delivering the finished molecule directly. Oral precursors like NR and NMN bypass this issue by entering the body as molecules the cell's own enzymes are already equipped to convert. For most people, oral precursors are both more practical and better studied than direct NAD+ administration.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for NAD+ optimization in one place.